SLU-PP-332 means “Saint Louis University – PPARδ Project, Compound #332a synthetic agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ), especially acting more potently at ERRα (EC₅₀ ≈ 98 nM) (Wikipedia):
Main Benefits (Preclinical Findings)
1. Metabolic Health & Fat Reduction
- Significantly reduces body weight (~18–24%) and white adipose tissue mass (~30–35%) in obese mouse models (Wikipedia).
- Enhances glucose metabolism: ~40%
improvement in glucose tolerance, ~25–30% reduction in fasting insulin levels (Wikipedia).
- Lowers blood lipids and improves liver health—reducing hepatic steatosis and inflammation.
2. Exercise Mimetic & Muscular Endurance
- Mimics aerobic exercise at the molecular level by activating
ERR-mediated pathways.
- Increases mitochondrial density (up to ~1.8-fold) in skeletal muscles and upregulates GLUT4, enhancing glucose uptake and oxidation (Wikipedia).
- Enhances running capacity by 30–40%, shifts muscle fiber composition toward oxidative types, and increases vascular density (Wikipedia).
3. Mitochondrial & Aging-Related Benefits
- Restores mitochondrial respiration in aged kidney and liver tissues.
- Reduces markers of inflammation (e.g., IL-6, TNF-α), oxidative damage, and fibrosis; improves autophagy and mitophagy (Wikipedia).
4. Cardioprotective Effects
- In models of heart failure and ischemia-reperfusion, it:
- Preserves cardiac contractility
- Reduces cardiomyocyte death
- Enhances fatty acid oxidation and energetics
- Attenuates pathological cardiac remodeling (Wikipedia).
5. Renal Protective Effects
- Reverses aging-associated kidney damage; improves mitochondrial function, reduces inflammation, and improves structural integrity via cGAS–STING and STAT3 signaling pathways.
Mechanism of Action
SLU-PP-332 activates ERRs, especially ERRα, which
regulate genes related to:
- Mitochondrial biogenesis (via TFAM, PGC-1α)
- Oxidative phosphorylation
- Fatty acid metabolism (e.g., via CPT1, MCAD)
- Energy sensing and endurance pathways (e.g., AMPK activation) (Wikipedia).
These effects essentially replicate many of the beneficial adaptations from aerobic training—even without actual exercise.
Status & Caveats
Aspect | Details |
Research Stage | Fully preclinical—tested only in cell and animal models; no human clinical trials yet (Wikipedia). |
Safety Profile | Limited data; mild hyperthermia, increased heart rate, and transient liver enzyme elevations observed in animal studies at higher doses (Wikipedia). |
Limitations | Off-target activity may occur at higher concentrations (>5 μM); complex synthesis and pharmacokinetic challenges like twice-daily dosing required (Wikipedia). |
Summary of Potential Benefits (Based on Preclinical Models)
- Promotes weight loss and reduces fat mass
- Improves insulin sensitivity and glucose metabolism
- Mimics exercise adaptations: boosts endurance, mitochondrial function, and oxidative metabolism
- Supports aging tissue health: improves mitochondrial function
in kidney and liver, reduces inflammation
- Protects cardiac function in disease models
Takeaway
SLU-PP-332 is a powerful preclinical “exercise mimetic” with metabolic, mitochondrial, cardiac, and renal benefits. While highly promising in animal studies, it remains experimental—with no current approval or human safety data. It’s strictly a research tool at this point.
